CORDIS
EU research results

CORDIS

English EN
Modeling spontaneous Breast cancer metastasis TO the Bone with a first-of-its-kind 3D device that recapitulates physiological tissue-level complexity.

Modeling spontaneous Breast cancer metastasis TO the Bone with a first-of-its-kind 3D device that recapitulates physiological tissue-level complexity.

Objective

Cancer patients developing a metastatic disease are considered incurable. Breast cancer hits 1 woman in 8, and its most common metastatic site is the bone. A major hurdle to overcome breast cancer mortality is the lack of understanding of dynamics leading to the spread of breast cancer cells to the bone. Consequently, metastasis-suppressing agents have not been found to date, neither as newly developed drugs nor as repurposing of existing ones. The aim of the B2B device is to generate a first-of-a-kind 3D model of spontaneous breast cancer metastasis to the bone to dissect the complexity of the metastatic process and empower high-throughput drug screening in a physiological context. B2B will pursue its goal of developing a novel hybrid device able to 1) propagate patient-derived tumor organoids of clinically-relevant dimensions, with their own self-assembled micro-capillary networks, which are 2) continuously linked to a 3D bioprinted macro-vascular tree, organized in a hierarchical branched structure, connected in a closed circuit with 3) a vascularized marrow-containing bone ossicle, as the metastatic target. This is a unique approach, spanning the micro (single circulating metastatic cells, passing the endothelial barrier of capillary networks) to macro (tumor organoids and ossicles of clinically relevant size and tissue composition, connected by a hierarchically organized vascular tree) continuum to recapitulate spontaneous bone metastasis formation in breast cancer. This technology will transcend the limitations of current in vitro technologies, enabling physiological tissue-level complexity with organoids comprising several million cells, and its expected impact will be three-fold: to recapitulate the spontaneous metastatic process in breast cancer, to provide a breakthrough technology to investigate metastasis longitudinally and at the single cell level, and to lead to the identification of metastasis-suppressing therapies for breast cancer patients.

Coordinator

CONSIGLIO NAZIONALE DELLE RICERCHE

Address

Piazzale Aldo Moro 7
00185 Roma

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 711 887,50

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAT BASEL

Switzerland

EU Contribution

€ 1 198 345

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 464 383,75

CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED

United Kingdom

EU Contribution

€ 234 242,50

REACT4LIFE SRL

Italy

EU Contribution

€ 406 600

IN SRL

Italy

EU Contribution

€ 230 587,50

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 390 825

BIOEMISSION TECHNOLOGY SOLUTIONS IKE

Greece

EU Contribution

€ 162 500

Project information

Grant agreement ID: 801159

Status

Ongoing project

  • Start date

    1 July 2018

  • End date

    30 June 2022

Funded under:

H2020-EU.1.2.1.

  • Overall budget:

    € 3 799 371,25

  • EU contribution

    € 3 799 371,25

Coordinated by:

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy